Inovio Pharmaceuticals (INO) FCF Margin (2010 - 2025)
Inovio Pharmaceuticals (INO) posted FCF Margin of 41218.49% for Q1 2025, down 145.24% sequentially from 16807.62% in Q4 2024.
Inovio Pharmaceuticals (INO) FCF Margin (2010 - 2025) Analysis & Trends
Inovio Pharmaceuticals has reported FCF Margin for 16 years, with the latest figure at 41218.49% in Q1 2025.
- Quarterly FCF Margin changed N/A year-over-year to 41218.49% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 136074.45% (down 8805539.0% YoY) and the FY2025 annual result came in at 136074.45%, down 8805539.0% from the prior year.
- FCF Margin retreated to 41218.49% in Q1 2025 per INO's latest filing, from 16807.62% in the prior quarter.
- Over five years, FCF Margin peaked at 737.94% in Q3 2022 and troughed at 41218.49% in Q1 2025.
- A 5-year average of 19712.55% and a median of 16807.62% in 2024 frame the typical range for FCF Margin.
- The widest YoY moves for FCF Margin: up 2234348 bps in 2022, down 2412171 bps in 2022.
- Over 5 years, FCF Margin stood at 4470.02% in 2021, then sank by 540 bps to 28591.73% in 2022, then climbed by 10 bps to 25597.2% in 2023, then surged by 34 bps to 16807.62% in 2024, then sank by 145 bps to 41218.49% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 41218.49%, 16807.62%, and 27556.39% for Q1 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -41,218.49% |
| Dec 31, 2024 | -16,807.62% |
| Jun 30, 2024 | -27,556.39% |
| Dec 31, 2023 | -25,597.20% |
| Sep 30, 2023 | -7,494.13% |
| Jun 30, 2023 | -14,442.36% |
| Mar 31, 2023 | -31,897.97% |
| Dec 31, 2022 | -28,591.73% |
| Sep 30, 2022 | -737.94% |
| Jun 30, 2022 | -6,490.91% |
| Mar 31, 2022 | -31,251.13% |
| Dec 31, 2021 | -4,470.02% |
| Sep 30, 2021 | -15,995.76% |
| Jun 30, 2021 | -28,834.39% |
| Mar 31, 2021 | -14,302.18% |
| Dec 31, 2020 | -910.20% |
| Sep 30, 2020 | -31,561.11% |
| Jun 30, 2020 | -10,175.30% |
| Mar 31, 2020 | -1,928.29% |
| Dec 31, 2019 | -4,602.65% |